Rejuran, PN and PDRN: Korean Skin Boosters Explained for Physicians

For two decades, aesthetic injection was an argument about volume. The question patients bring to my clinic now is different. They talk about texture, pores, glow and how their skin looks at close range in a front camera. Skin quality has moved from the finishing touch on a treatment plan to the plan itself, and in Korea the skin booster is where that shift shows most.

The category has also grown faster than the evidence and the regulation around it. New products reach the treatment room every season, often before anyone has settled what they contain, which plane they belong in, or what they must never be mixed with. So before protocols, let me start with the distinction that confuses the most colleagues.

One habit first, though: read the tissue before you choose anything. Facial fat sits in compartments, not one pad, and a change in skin hydration or texture is not the same endpoint as restoring volume. Keep those two goals apart, in your plan and in your consent. Explain the intended outcome and the product-specific risks for each planned procedure.

PN and PDRN are not the same thing

You will hear "Rejuran" and "PDRN" used as if they were one product. They are not, and the difference matters for how you read the evidence.

PDRN (polydeoxyribonucleotide) is a mixture of DNA-derived nucleotide polymers studied for tissue repair. The often-quoted link to adenosine A2A receptor signalling comes from experimental work in a diabetic-mouse wound model, where blocking A2A reversed the healing effect. That supports a proposed pathway in that model. It is not a promise of a cosmetic result. The best-known human trial is in chronic diabetic foot ulcers, and wound repair in that population is a different question from facial texture or redness.

PN (polynucleotide) products in this clinical context are generally described as longer DNA-derived chains than PDRN preparations and are formulated as injectable gels. Their water-binding gel structure provides a rationale for hydration and scaffold-like physical support within the tissue. That describes the material's intended role; chain length alone does not establish how long a product remains in human skin or guarantee sustained regeneration or a longer clinical effect.

For PN, the evidence that counts is the evidence for that particular formulation and indication. In a small randomised split-face study around the eyes, a PN product was compared with non-crosslinked HA. Some measured skin-quality outcomes favoured PN, but the overall aesthetic ratings did not differ significantly. That is an honest result, and it does not show that every PN product is the same or that PN always beats HA.

My rule at the chair: read beyond the abbreviation. A shared DNA-related name does not make two products interchangeable. Do not carry a PDRN wound-healing study over to a PN gel, and do not assume the same composition, viscosity, dose or regulatory status from the name.

The Korean skin booster toolbox

In Korea we rarely use a booster alone. We combine agents by mechanism into what we call cocktails, matched to skin type and the main concern. The building blocks fall into a few classes:

• Support / DNA-based — PN and PDRN: repair signalling (PDRN), scaffold and water binding (PN). Intradermal.
• Hydration — HA skin boosters: bind water and smooth the surface. Intradermal.
• Biostimulators — synthetic (PLLA, PCL, PDO particles, CaHA) or autologous (PRP, PRF): provoke collagen over weeks. Deeper planes.
• Adjuncts — intradermal toxin ("skin botox") for oil and texture, and peptides.

Two labels mislead more than others. Amino-acid solutions are a substrate and a diluent, not a biostimulator. And exosome products are not FDA-approved; the FDA has issued safety warnings about injected exosomes, and our Fact Sheet does not recommend injecting them.

And small is not the same as proven. NMN, now paired with HA in some Korean boosters, is one of the few actives small enough to approach the skin's roughly 500-dalton barrier. But for intradermal cosmetic use there are no clinical data. If you use it, tell your patient exactly that.

The principle under all of it: choose the agent by the mechanism you need, then let the mechanism decide the plane. Almost everything that goes wrong with boosters goes wrong because a product was put at the wrong depth. Where on the face you place a product is your clinical decision, and no single technique fits every patient. What stays constant is the depth.

Plane comes first

PN, PDRN and HA skin boosters are used intradermally in the protocols discussed here; precise placement must match the selected product and treatment site. Biostimulator particles such as PLLA, PCL and PDO go deep dermis, subcutaneous or supraperiosteal, never into the superficial dermis. CaHA is subdermal, never intradermal. With a biostimulator, immediate blanching means you are too superficial: withdraw and go deeper. And know what is in the vial. Ultracol is PDO with CMC and PiNkLLA is PLLA with PN; their regulatory status must be checked for the exact product and market.

For PN, my preferred tool for broader treatment fields is a suction-assisted multi-needle injector, with manual 33–34 G needle placement for delicate, thin or contoured areas. The product, treatment site and actual tissue plane determine the technique. A device's displayed depth or nominal volume is a setting, not proof of the depth or amount delivered within the tissue.

A blunt cannula is a separate, selected option rather than an interchangeable way of performing the same dermal microdroplet protocol. Published periorbital protocols vary by formulation and technique; any cannula approach requires its own product and plane assessment.

What about applying boosters after microneedling or laser? Almost every booster molecule is far larger than what intact skin lets through, so "topical" only means something on a channelled skin bed. Small trials suggest added benefit for PN and PDRN on channelled skin, but injection remains the reference standard. I say that plainly to patients.

How the protocols are built

In our Skinboosters Fact Sheet the protocols are organised by skin type and concern rather than by product. A short overview:

• Fine lines, pores, texture — an HA skin booster with a separate intradermal toxin pass, repeated every three to six months. PN and other agents can fill the interval.
• Acne, scars, pigment, dullness — PN plus a signalling agent (autologous PRF/PRP or another option), with or without intradermal toxin, every two to four weeks for three to four sessions.
• Post-laser recovery — PN with PRF/PRP on freshly treated skin, no toxin, starting on the laser day and repeated every three weeks for three sessions.
• Laxity and mature skin — a biostimulator-based protocol every two to four weeks for three to four sessions, because collagen builds gradually.

The full combination formulas and preparation steps are in the Fact Sheet; the standalone PN volumes discussed below are provided separately. Two rules apply to all of them. If the cocktail uses the patient's own PRF or PRP, toxin is never mixed in, because plasma proteins reduce toxin activity; it is given as a separate pass. And freshly lasered or channelled skin is an open wound, so sterility is the procedure.

Standalone PN: volumes and delivery

For the standalone PN approach described here, my usual full-face starting volume is 2.0 mL, with 2.0–4.0 mL considered according to the selected product, treatment area and patient assessment. For a localised field such as the periocular area, neck or backs of the hands, the planning range is 1.0–2.0 mL; an eye-specific formulation may use 1.0 mL. Volume alone does not describe the treatment: PN concentration, formulation and the product's instructions also matter. A larger volume is not automatically appropriate because the skin is thin.

For manual dermal microdroplets, the reference range supplied for this protocol is 0.01–0.03 mL per point, with spacing of about 0.5–1.0 cm. Small visible wheals help assess the intended dermal placement, but wheal size is not a measurement of exact delivered dose. The pattern and volume need to be adjusted to the site and formulation; neither the grid nor one fixed millimetre depth fits every face.

Patients should be told that injection discomfort, swelling and bruising can occur. Topical anaesthesia may reduce discomfort without guaranteeing a painless procedure. Pain that is severe, unexpected or worsening needs assessment.

First course and maintenance

For a first-time patient having PN alone, I generally plan an initial course of 3–4 sessions at 2–4-week intervals, most often 3–4 weeks apart. After that course, a maintenance session may be considered at 3–6-month intervals, depending on the response, treatment goal and selected product. This is a practical clinical plan that is reassessed along the way, rather than a fixed number every patient must complete.

I explain the course as a chance to assess gradual change in skin quality over successive visits. We review texture, hydration, fine lines and the patient's own experience before deciding on the next treatment or maintenance. I would not promise that collagen structure is completed at a particular visit or that a given session guarantees a specific change.

PN boosters vs HA boosters

HA skin boosters are chosen chiefly for water-binding hydration. PN gels also bind water and offer scaffold-like physical support, while their potential roles in tissue repair and remodelling continue to be studied. At the chair, I describe HA as helping create a hydrated environment and PN as providing hydration and tissue support. These are differences in emphasis, not exclusive functions or separate anatomical layers. Both may be used in the dermis, with placement determined by the particular product and treatment site. The choice starts with the patient's concern and the evidence for the selected formulation.

On evidence, be modest in both directions. The one randomised PN-versus-HA study we cite is small and found no significant difference in the overall aesthetic rating. In the US, SKINVIVE by JUVÉDERM has product-specific FDA approval for cheek skin smoothness and, since June 2026, neck lines in adults over 21. This does not establish approval for PN or PDRN products. Regulatory authorization must be checked for each product, indication and country.

A practical point for colleagues outside Korea: if a distributor tells you a booster is "FDA", ask what that means. A cosmetic listing, an establishment registration or a CE mark is not FDA approval. Read the label as well: some "ampoules" sold alongside boosters say apply to the face, which makes them topical products. If you use a product that is not approved in your country, your written consent should say so, and for a biostimulator it should also name the risk of a nodule that cannot be reversed.

Safety and contraindications

DNA-based boosters still require product-specific risk assessment, including hypersensitivity to their components. My pre-session checklist covers active infection or inflammation at the site, known hypersensitivity to any component, pregnancy or breastfeeding, keloid tendency if you plan to channel, and unrealistic expectations. For patients with a history of cold sores, I give prophylaxis before any channelling or laser session.

Any late nodule should make you think about infection before blaming the product, and remember that PLLA nodules can appear months later, with a median onset of around 160 days. If a cocktail session also includes particulate fillers, learn to recognise vascular occlusion in seconds: pain out of proportion, blanching and then dusky mottling, or any change in vision. Stop and run your written vascular occlusion protocol, which we cover in the HA Filler Fact Sheet. Hyaluronidase dissolves HA only; PLLA, PCL, PDO and CaHA cannot be dissolved.

Two irreversibles govern this work: a particle you cannot dissolve, and an infection you cannot take back. Everything else is adjustable.

I close my lecture on this subject with one line, and it fits here too: it is not the untouched, but the well-touched, that age gracefully.

Frequently asked questions

This article is educational material for medical professionals. It does not replace product labelling, local regulation or clinical judgement. Product names are mentioned for identification only.